2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2909

Efficacy and Safety of the Selective Interleukin-1 Receptor Associated Kinase 4 Inhibitor, PF-06650833, in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
Abstract Number: 2910

Improving the Efficiency of Clinical Trial Recruitment Using Electronic Health Record Data, Natural Language Processing, and Machine Learning
Abstract Number: 2911

A Randomised, Open Labelled Clinical Trial to Investigate Synovial Mechanisms Determining Response – Resistance to Rituximab versus Tocilizumab in Rheumatoid Arthritis Patients Failing TNF Inhibitor Therapy
Abstract Number: 2912

Predictive Factors for Treatment Related Mortality and Event-Free Survival After Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis: Results of a Long Term Follow-up Multi-centre Study
Abstract Number: 2913

Serum Interferon Score Predicts Clinical Outcome at 12 Months in Diffuse Cutaneous Systemic Sclerosis as Measured by Global Ranked Composite Score (GRCS) and Composite Response Index in SSc (CRISS)
Abstract Number: 2914

Predictors to Develop Definite Systemic Sclerosis (SSc): Results from an International Multicentre Study on Very Early DiagnOsis of Systemic Sclerosis (VEDOSS)
Abstract Number: 2915

Machine-learning Classification Identifies a Subset of Patients That Improve on Abatacept via Modulation of a CD28-Related Pathway
Abstract Number: 2916

Ancestry-Specific Classical HLA Alleles Define Phenotypic Subsets in the African American Scleroderma Population
Abstract Number: 2917

Geographic Disparities in Systemic Sclerosis Mortality in the United States: 1999 to 2017
Abstract Number: 2918

Metabolic Signatures of Pathogenic T Cells in Medium and Large Vessel Vasculitis
Abstract Number: 2919

Endothelial Protein C Receptor and Scavenger Receptor Class B Type 1 Negatively Regulate Vascular Inflammation and Are Major Autoantigens in Takayasu Arteritis
Abstract Number: 2920

Comparison of Arterial Patterns of Disease in Takayasu’s Arteritis and Giant Cell Arteritis
Abstract Number: 2921

High Resolution 3D Fast Spin-Echo T1 Black-Blood Imaging for the Diagnosis of Giant Cell Arteritis
Abstract Number: 2922

Imaging Acquisition Technique Influences Interpretation of Positron Emission Tomography Vascular Activity in Large-Vessel Vasculitis
Abstract Number: 2923

Clinical Subsets in Giant Cell Arteritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].